Gianni L et al. reported that H + P yielded higher PCR rates in HR−/HER2+ breast cancer compared with those achieved in HR+/HER2+ breast cancer (63.2 and 26.0%, respectively) [15], and M. Martin et al. reported a 36.5% improvement in the outcomes of pCR after H + P therapy in the comparison of HR−/HER2+ and HR+/HER2+ breast cancer patients. Here, ERBB2 is linked to breast carcinoma.